| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |